CASI Pharmaceuticals

CASI Pharmaceuticals

CASI Pharmaceuticals was founded in 1991 and is led by Chairman and CEO Wei-Wu He, a Chinese-American scientist-entrepreneur who previously founded OriGene Technologies. The company operates a dual-headquarters model with a commercial team in Beijing and a business-development and investor-facing office in Rockville, Maryland. This trans-Pacific architecture defines its operating model: sourcing U.S. and European biotech assets that are deprioritized by their originators and commercializing them for the China market through a Beijing-based hematology-oncology sales force. The firm's strategy centers on acquiring or in-licensing late-stage and commercial hematology-oncology therapeutics with established clinical data, then registering, manufacturing, and distributing them in China. Its commercial portfolio includes EVOMELA (melphalan for injection), an conditioning agent used in stem cell transplantation in multiple myeloma patients, in-licensed from Spectrum Pharmaceuticals. The pipeline has included assets like CID-103, an anti-CD38 monoclonal antibody for multiple myeloma, and BI-1206, an anti-FcγRIIB antibody. CASI deploys capital through direct asset acquisitions, regional licensing deals, and co-development agreements rather than traditional fund structures, with the geographic scope heavily concentrated on Greater China. The company employs a lean operating model, carrying a commercial team in China supported by corporate functions in Maryland. In November 2024, CASI received notification from Nasdaq regarding non-compliance with the minimum market value of listed securities requirement, adding to ongoing exchange listing pressures (per public filings, 2024). Under He's continued leadership, the firm has undergone multiple restructurings aimed at preserving cash and focusing the pipeline on near-term revenue-generating assets. CASI's fundamental structural feature is its role as a cross-border regulatory and commercial bridge. Unlike a venture-stage biotech that builds around scientific platforms, CASI acts as a China-market access channel for de-risked Western assets. This requires fluency in U.S. and Chinese drug-registration pathways, local GMP manufacturing partnerships, and a direct hospital sales force — a bundled capability set that is difficult for Western biotechs to replicate independently without building their own China infrastructure.